Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02053766
Other study ID # HSC-MS-13-0600
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 10, 2014
Est. completion date September 2022

Study information

Verified date September 2020
Source The University of Texas Health Science Center, Houston
Contact Stephanie Maldonado
Phone 713-828-4291
Email Stephanie.Maldonado@uth.tmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study is a prospective, randomized clinical trial to evaluate the effect of anesthesia in the mitochondrial dysfunction patient.


Description:

Study subjects undergoing a routine medical care non-emergent procedure will be randomized into three different groups to receive one of the following anesthetic agents; Sevoflurane, Propofol or Dexmedetomidine.

The primary outcome of this pilot study is to evaluate and compare the incidence of adverse events in mitochondrial patients undergoing a diagnostic or therapeutic procedure up to 48 hours post anesthesia. The secondary outcome is to compare the metabolic derangements between three study groups by comparing changes in blood sugar, serum pH, serum bicarbonate, serum lactate and serum pyruvate levels before, during and after anesthesia in the groups.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date September 2022
Est. primary completion date September 2022
Accepts healthy volunteers No
Gender All
Age group N/A to 17 Years
Eligibility Inclusion Criteria:

- Subjects must fulfill the following inclusion criteria:

- Subject is informed and given ample opportunity to consider his/her participation and has given his/her written consent.

- Subject is willing and able to comply with all study requirements.

- Subject is between 0 - 17 years of age.

- Subject has been diagnosed with mitochondrial dysfunction based on modified Walker criteria.

- Subject is scheduled to have a non-emergent diagnostic or therapeutic procedure for routine medical care requiring general anesthesia estimated to last at least one hour.

- Subject is classified ASA I - IV

Exclusion Criteria:

Subjects are not permitted to enroll in the study if any of the following criteria are met:

- Subject is older than 17 years

- Subject is pregnant

- Subject is a nursing female and

- Subject has participated in the same study within 48 hours

- Subject is allergic or has had any adverse effect to any of the study agents in the past

- Anesthesia time is less than one hour

- Subject is classified ASA V

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sevoflurane
Sevoflurane up to 8% will be administered to study subjects
Dexmedetomidine
Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.
Propofol
Propofol up to 50 mcg/ kg/min will be administered to study subjects.

Locations

Country Name City State
United States University of Texas Health Science Center at Houston Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome measure of this study is to evaluate and compare the incidence of adverse events in mitochondrial patients undergoing a diagnostic or therapeutic procedure between the three drug groups. An adverse event (AE) is any untoward medical occurrence in a subject, compared with pre-existing condition that occurs during any phase of the research study. An AE is defined as being independent of assumption of any causality. The following laboratory values and physical findings are to be considered AEs:
Laboratory value(s) of blood glucose, serum lactate, serum pyruvate, serum bicarbonate and pH that change from a subject's baseline by greater than 10% and is outside the normal range.
Any of the following parameters; feeding difficulties, temperature >100 F, vomiting, nausea, lethargy, change in admission plan and any other change in baseline that are clinically relevant.
Up to 48 hours post anesthesia.
See also
  Status Clinical Trial Phase
Completed NCT03388528 - Low Residue Diet Study in Mitochondrial Disease N/A
Completed NCT04378075 - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Phase 2/Phase 3
Completed NCT03678740 - Diagnostic Odyssey Survey 2
Recruiting NCT06051448 - Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Phase 1/Phase 2
Completed NCT02909400 - The KHENERGY Study Phase 2
Completed NCT02398201 - A Study of Bezafibrate in Mitochondrial Myopathy Phase 2
Completed NCT03857880 - Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip
Not yet recruiting NCT06450964 - Establishment of Reproductive Cohort and Prediction Model of Genetic Counseling for Mitochondrial Genetic Diseases
Completed NCT04165239 - The KHENERGYZE Study Phase 2
Completed NCT02284334 - Glycemic Index in Mitochondrial Disease
Recruiting NCT06080581 - Mitochondrial Dysfunctions Driving Insulin Resistance
Recruiting NCT06080568 - Human Mitochondrial Stress-driven Obesity Resistance
Recruiting NCT04802707 - Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome Phase 2
Completed NCT04580979 - Natural History Study of FDXR Mutation-related Mitochondriopathy
Completed NCT04594590 - Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
Withdrawn NCT03866954 - Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy Phase 2
Recruiting NCT04113447 - Mitochondrial Donation: An 18 Month Outcome Study.
Enrolling by invitation NCT04734626 - CrCest Study in Primary Mitochondrial Disease
Completed NCT03832218 - Executive Function Disorders and Anxio-depressive Symptomatology in Children and Adolescents With Mitochondrial Pathologies N/A
Terminated NCT02473445 - A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease Phase 2